Current Advances in the Discovery and Development of New Therapies against Cancer, 2nd Edition
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: 30 April 2026 | Viewed by 20
Special Issue Editor
Interests: tumor immunology; immunotherapy; tumor microenvironment
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Treating cancer, including leukemias and solid tumors, is a challenging task, as there are only a few approved therapeutic options besides chemo-radiotherapy and surgery, and they often fail in extending survival for patients. Additionally, the ever-changing nature of these diseases has made it almost impossible to improve treatment outcomes. For these reasons, researchers have focused on the discovery, development, and possible mechanisms of targeted therapies for cancer. Molecular targeted therapies, nanotherapy, and immunotherapy are strategies that could be used alone or combined with standard treatments, leading to better disease outcomes, as well as improved survival.
Our aim is to provide a broad overview of the most recent advances in the discovery and development of therapies that could have the potential to target solid tumors and leukemias, as well as the repositioning of old drugs, initially used against other diseases, to be used to target these tumors.
The Guest Editors of this Special Issue welcome the submission of high-quality original research articles, reviews.
We are especially interested in receiving papers exploring, but not limited to, the following topics:
(a) The development and discovery of new cancer drugs, especially those designed to target solid tumors and leukemias;
(b) The development and discovery of new cancer drugs, especially against SNC tumors;
(c) The development and discovery of new therapies that combine chemotherapeutic agents with molecular targeted therapy and agents that target genes and/or proteins involved in cellular metabolism;
(d) The development and discovery of new therapies that combine chemotherapeutic agents with nanotherapy;
(e) In vitro, in vivo, and preclinical studies that show the use of new therapies (either alone or combined with the standard treatment) targeting cancer;
(f) In vitro, in vivo, and preclinical studies that demonstrate drug repositioning to tackle cancer;
(g) Reviews focused on the “state of the art” in cancer drugs and new therapies against cancer.
Dr. Benjamin Pineda
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- solid tumor
- leukemia
- central nervous system
- tumor
- drug discovery
- therapy
- nanotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
